Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference study

BACKGROUND: Historically, high hepatocellular carcinoma (HCC)–related mortality has been, in part, due to lack of effective therapies; however, several systemic therapies have been recently approved for HCC treatment, including regorafenib and ramucirumab. These two treatments utilize different rout...

Descripción completa

Detalles Bibliográficos
Autores principales: Parikh, Neehar D., Girvan, Allicia, Coulter, Joshua, Gable, Jonathon, Poon, Jiat Ling, Kim, Sangmi, Chatterjee, Anindya, Boeri, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851100/
https://www.ncbi.nlm.nih.gov/pubmed/36658529
http://dx.doi.org/10.1186/s12885-022-10388-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851100/
https://www.ncbi.nlm.nih.gov/pubmed/36658529
http://dx.doi.org/10.1186/s12885-022-10388-8

Ejemplares similares